New pneumococcal 15-valent conjugate vaccine that includes coverage against serotype 3

Description

In this Product Explainer, Public Health Physician and Infectious Diseases Epidemiologist Prof Paul Van Buynder explains the burden of pneumococcal disease in both children and adult population. He explains why PCV 15 has increased serotype coverage and why improved immunogenicity against serotype 3 is important both from a clinical and public health perspective (5 mins).

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
A/Prof Samantha Hocking

A/Prof Samantha Hocking

Tirzepatide Compared to Semaglutide for Treatment of Obesity – Latest Evidence

A/Prof Gino Pecoraro OAM

A/Prof Gino Pecoraro OAM

Genitourinary Syndrome of Menopause – Mythbusting for GPs

Prof Sonia Grover

Prof Sonia Grover

Dysmenorrhoea in Teens

Prof Paul Griffin

Prof Paul Griffin

Winter Virus Preparations

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Prof Paul Van Buynder

expert

Prof Paul Van Buynder

Public Health Physician and Infectious Diseases Epidemiologist; Professor, School of Medicine, Griffith University, Queensland

Date published: 1 January 1970